EUVIMEDSkopri EUVIMED
Crossref

Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon

Alexa Carboni, Sabrina Woessner, Olnita Martini, Nathaniel A Marroquin, Jacquelyn Waller

Journal of Drugs in Dermatology · 2024-01-01 · 23 (1) · 1367-1368

DOI: 10.36849/jdd.7613 ↗

At a glance

Journal article in Journal of Drugs in Dermatology, published online on 2023-12-01. Written by Alexa Carboni and 4 co-authors. Major MEDLINE topics: Diabetes Mellitus, Type 2, Social Media, Glucagon-Like Peptides. Cited 48 times so far (Crossref).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

New patients turning to semaglutide (Ozempic® and Wegovy®), a glucagon-like-peptide 1 (GLP-1) agonist, for weight loss, have captivated social media platforms. Wegovy® carries a United States (US) Food and Drug Administration (FDA) approval for chronic weight management in patients who have a body mass index (BMI) 27 kg/m2 or greater and at least one weight-related condition (eg, hypertension, type 2 diabetes, cholesterol) or in patients with a 30 kg/m2 or greater BMI. Although other semaglutide formulations are not FDA approved for weight loss, the term "Ozempic face" has consumed the media with the medication's rising popularity. This term is a new purported side effect, used to describe the rapid facial weight loss leaving a distorted facial appearance. This challenges the healthcare team to discern whether a new adverse effect is a novel or a natural consequence of rapid weight loss. Dermatologists are well positioned to counsel patients receiving or discontinuing GLP-1 agonists and recommend appropriate countermeasures, as appropriate. J Drugs Dermatol. 2024;23(1):1367-1368. doi:10.36849/JDD.7613.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Social MediaGlucagon-Like PeptidesUnited StatesHumansGlucagon-Like Peptide 1Weight LossSemaglutide

Substances

Glucagon-Like Peptide 1Glucagon-Like PeptidesSemaglutide

Cite

APA

Carboni, A., Woessner, S., Martini, O., Marroquin, N. A., & Waller, J. (2024). Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon. Journal of Drugs in Dermatology, 23(1), 1367-1368. https://doi.org/10.36849/jdd.7613

Vancouver

Carboni A, Woessner S, Martini O, Marroquin NA, Waller J. Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon. Journal of Drugs in Dermatology. 2024;23(1):1367-1368. doi:10.36849/jdd.7613

BibTeX
@article{Carboni2024,
  author = {Carboni, Alexa and Woessner, Sabrina and Martini, Olnita and Marroquin, Nathaniel A and Waller, Jacquelyn},
  title = {Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  volume = {23},
  number = {1},
  pages = {1367--1368},
  doi = {10.36849/jdd.7613}
}
Start for free →